SCHEMBL4471443

SCHEMBL4471443

Cc1cccc(-c2nc(CI)c(-c3ccccc3)o2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.54
RAB9A P51151 7/20 0.54
SMN1; SMN2 Q16637 7/20 0.54
HPGD P15428 4/20 0.54
TSHR P16473 1/20 0.54
NOTUM Q6P988 1/20 0.46
RXRA P19793 2/20 0.45
RXRB P28702 2/20 0.45
RXRG P48443 2/20 0.45
NR4A2 P43354 1/20 0.45
L3MBTL1 Q9Y468 2/20 0.45
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
KDM4E B2RXH2 3/20 0.43
CASP3 P42574 2/20 0.43
SENP8 Q96LD8 2/20 0.43
SENP7 Q9BQF6 2/20 0.43
SENP6 Q9GZR1 2/20 0.43
POLB P06746 2/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1051296 0.85 RAB9A (0.53) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL1045451 0.85 MAPT (0.49) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL1047698 0.82 ALDH1A1 (0.54) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL1079945 0.81 KDM4E (0.44) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL1047012 0.74 KDM4E (0.64) NPC1RAB9AHPGDKDM4ETP53
SCHEMBL5484160 0.74 NPC1 (0.47) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL13767787 0.73 MAPT (0.52) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL1436140 0.73 MAPT (0.49) NPC1RAB9ASMN1; SMN2HPGDTSHR
SCHEMBL1051419 0.72 KDM4E (0.60) NPC1RAB9ASMN1; SMN2HPGDKDM4E
SCHEMBL22549565 0.71 KDM4E (0.59) SMN1; SMN2TSHRKDM4EPOLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7598281-B2 Arylcycloakyl-substituted alkanoic acid derivatives useful as peroxisome proliferator-activated receptor (PPAR) ligands for the treatment of hyperlipidemia and diabetes SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2009-10-06 US disclosed
US-20070197605-A1 ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) 2007-08-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070197605-A1 ARYLCYCLOAKYL-SUBSTITUTED ALKANOIC ACID DERIVATIVES USEFUL AS PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) LIGANDS FOR THE TREATMENT OF HYPERLIPIDEMIA AND DIABETES PPARA, PPARG, GPR119 NPC1 732/4885RAB9A 3339/4885SMN1; SMN2 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.